CN Bio logoCN Bio logoCN Bio logoCN Bio logo
  • Products
    • Explore our solutions


      PhysioMimix™ products enable you to recreate complex human biology and accurately predict human drug responses

      PhysioMimix OOC

      PhysioMimix OOC systems
      Learn more

      Consumables

      • Multi-chip plates
      • 3D validated cells
      • NASH-in-a-box
      Learn more

      Models

      • Single-organ models
      • Multi-organ models

      Support packages

      • PhysioMimix™ support packages
  • Applications
    • Discover the applications


      Investigate the application areas that our PhysioMimix™ products and services support

      Learn more

      Disease modeling

      • Non-Alcoholic Steatohepatitis
      • Hepatitis B
      • Oncology
      • COVID-19
      Learn more

      Safety toxicology

      • Drug-induced liver injury
      • Immune-mediated toxicities
      Learn more

      ADME

      • Drug absorption
      • Drug metabolism
      • Drug bioavailability
      Learn more
  • Services
    • Studies as a service


      Our team will work collaboratively with you to design a study around your research goals and generate actionable data within weeks

      Learn more
      NAFLD / NASH icons

      NAFLD / NASH

      Drug-induced liver injury icon

      Drug-induced liver injury

      icon adme |

      ADME

      Oncology icon

      Oncology

  • Resources
  • Company
    • About us


      Meet the team, explore our culture and discover what to expect when working with us

      CN Bio team photo
      About us

      Latest news

      • The FDA further expands collaboration with CN Bio to evaluate the PhysioMimix Multi-organ microphysiological system

      • The U.S. FDA Modernization Act 2.0. Now the animal testing mandate is removed, learn what can be embraced in its place.

      • CN Bio appoints Dr Paul Brooks as Chief Executive Officer

      View all news

      Upcoming Events

      • SLAS2023

      • SOT 2023

      • WORD 2023

      • SLAS Europe 2023

      • MPS World Summit 2023

      View all events

      Join the team!

      View all jobs
  • Contact
  • Products
    • PhysioMimix™ OOC Microphysiological Systems
    • Consumables
      • PhysioMimix™ multi-chip plates
      • 3D validated cells
      • NASH-in-a-box
    • Organ-on-a-chip models
    • Support packages
  • Applications
    • Disease modeling
    • Safety toxicology
    • ADME
  • Services
    • Non-Alcoholic Steatohepatitis
    • Drug-Induced Liver Injury
    • ADME
  • Resources
  • Company
    • About us
    • Events
    • News
    • Careers
  • Contact
  • Skip to main content
  • Skip to footer
Chat live with an expert

Organ-on-a-Chip Resources

Resource type

Area of interest

Articles

Resource image

ADME Studies: Determining Promising Drug Compounds

Dr Abbas discusses factors that can affect the outcome of an ADME study, signs that a drug compound shows promise, red flags, and key parameters to determine safety and efficacy.

This article is taken from PharmTech, November 2022.

Articles

Resource image

How to Keep Breathing – The Future of Inhaled Medication Testing

Dr Emily Richardson discusses the current challenges faced to bring inhaled therapeutics to the market and the potential of Organ-on-a-Chip to increase positive outcome by improving ADME drug testing.

This article is taken from International Biopharmaceutical Industry, Summer 2022.

Videos and animations

Resource image

PhysioMimix Multi-organ System Animation

An introduction to the CN Bio PhysioMimix Multi-organ System. This animation demonstrates how our microphysiological system works, how to create a Gut/Liver-on-a-chip model and an example of its use.

Scientific publications

Resource image

Application of a gut–liver-on-a-chip device and mechanistic modeling to the quantitative in vitro pharmacokinetic study of mycophenolate mofetil

Milani et al., 2022

This study shows how an in vitro gut-liver multi-organ model can quantitatively recapitulate the in vivo metabolism of a drug. By combining Organ-on-a-chip with in silico modeling, the study also demonstrates the potential of multi-organ models for quantitative estimation of PK parameters of a drug and its metabolites.

Posters

Resource image

Normalization of organ-on-a-chip samples for mass spectrometry based proteomics and metabolomics via dansylation-based assay

Gallagher et al

This poster shows the combined use of MS-based proteomics and metabolomics with organ-on-a-chip to better assess the classification of biological replicates in toxicity studies.

Posters

Resource image

Harnessing the power of multimodal imaging to explore ASO distribution in cells, complex in vitro models and tissue

Alex et al

This recent poster from GSK and collaborators features data from our PhysioMimix™ OOC and Liver (MPS-LC12) plates. The results demonstrate that the distribution of ASOs into Kupffer cells and circular or cuboidal hepatocytes cultured in 3D can be detected using imaging.

Scientific publications

Resource image

Exploration and Application of a Liver-on-a-Chip Device in Combination with Modelling and Simulation for Quantitative Drug Metabolism Studies

Docci et al., 2022

This publication explores the potential of the PhysioMimix liver model for investigating drug candidates for hepatic disease. This study integrates mathematical modeling with experimental liver-on-a-chip studies and demonstrates how this approach supports the generation of high-quality data from complex in vitro cellular systems.

Scientific publications

Resource image

Multiorgan microphysiological systems as tools to interrogate interorgan crosstalk and complex diseases

Trapecar, 2022

A review of the state of multi-organ microphysiological systems in 2021. Overviews of currently available multi-organ MPS and the different technologies, cells and physiological cues used. Discusses approaches for systems biology integration and how MPS can be more readily adopted in the wider research community.

Application notes

Resource image

Improved prediction of oral bioavailability using a gut-liver microphysiological system

Abbas, Kostrzewski & Hughes

Central to the development of new drugs is an understanding of their pharmacokinetic properties, in particular their bioavailability. Here, we demonstrate the potential of a true 2-organ gut-liver MPS to better predict human bioavailability and improve in vitro to in vivo correlation.

Webinars

Resource image

From Dose to Circulation: Determination of Drug Oral Bioavailability Using a Gut-Liver Microphysiological System

Webinar Series 4 Episode 4

In this webinar, Dr. Yassen Abbas discusses how CNBio’s gut-liver MPS can be used for in vitro determination of oral bioavailability. This application has been validated with drugs with known human bioavailability and with a mathematical model developed to enable prediction of oral bioavailability in silico.

Application notes

Resource image

Drug metabolism in a gut-liver microphysiological system

Abbas, Kostrzewski & Hughes

Studies investigating the efficacy and safety of candidate drugs use a variety of animal models to translate research from the bench to clinical trials and then to the clinic. Here, we demonstrate the potential of multi-organ MPS models for improved predictions of in vivo drug absorption and hepatic clearance rates.

Posters

Resource image

Microphysiological systems of the human liver, gut and linked liver-gut, to assess human drug absorption, metabolism and bioavailbility

Kostrzewski et al

This poster demonstrates the potential of human MPS models for liver, gut, and multi-organ (connecting gut with liver) for the investigation of human PK parameters, drug absorption and metabolism, and bioavailability.

Speak to our experts

Speak directly with one of our OOC experts to see how our products and services can support your studies

Request a meeting

Footer

CN Bio logo

332 Cambridge Science Park, Milton Road
Cambridge, CB4 0WN

+44 (0) 1223 737941

Privacy | Cookies | Terms | Regulatory | Accessibility

©2023 CN Bio Innovations Ltd
Registered No. ‍06517359. VAT No. 978184563

Latest news

  • The FDA further expands collaboration with CN Bio to evaluate the PhysioMimix Multi-organ microphysiological system January 17, 2023
  • The U.S. FDA Modernization Act 2.0. Now the animal testing mandate is removed, learn what can be embraced in its place. January 9, 2023
  • CN Bio appoints Dr Paul Brooks as Chief Executive Officer December 19, 2022

Upcoming events

MPS World Summit 2023 June 26-30, 2023

SLAS Europe 2023 May 22-26, 2023

SLAS2023 February 25 - March 1, 2023